Physician profile
Jack E Rashkin
NPI 1851399885
$5,894.37
in general payments reported to CMS, 2019-2025
46 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $968 · 2021: $813 · 2022: $854 · 2023: $930 · 2024: $350 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $827.32 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $519.73 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.01 | 2019-2024 | Ofev, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $452.16 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $312.87 | 2019-2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $281.82 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $266.35 | 2019-2025 | |
| Electromed, INC. | $193.76 | 2019-2025 | Smartvest |
| Janssen Pharmaceuticals, INC | $182.33 | 2019-2022 | |
| United Therapeutics Corporation | $167.80 | 2019-2022 | |
| Shionogi INC | $165.82 | 2021-2023 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $141.91 | 2020-2024 | Glassia |
| Mallinckrodt Hospital Products INC. | $139.15 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $135.81 | 2019-2022 | |
| Philips North America LLC | $115.86 | 2019-2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $114.48 | 2023-2025 | Inspire |
| Genzyme Corporation | $113.49 | 2019-2023 | |
| Mylan Specialty L.P. | $113.13 | 2019-2020 | |
| Intuitive Surgical, INC. | $98.48 | 2023 | Da Vinci Surgical System |
| Abbvie INC. | $93.03 | 2022-2023 | |
| Baxter Healthcare | $80.11 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Vapotherm INC | $67.14 | 2022 | |
| Genentech USA, INC. | $62.59 | 2019 | |
| Ambu INC. | $57.92 | 2020-2025 | |
| Advanced Respiratory, INC | $57.83 | 2019-2020 | |
| Grifols USA, LLC | $53.70 | 2020-2021 | |
| Gilead Sciences, INC. | $52.93 | 2019-2021 | |
| Csl Behring | $46.65 | 2019 | |
| Inogen, INC. | $46.01 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Shire North American Group INC | $42.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.51 | 2019-2021 | |
| Inari Medical, INC. | $41.32 | 2021 | |
| Amgen INC. | $39.18 | 2022-2023 | Tavneos |
| Merck Sharp & Dohme LLC | $38.94 | 2019 | |
| Paratek Pharmaceuticals, INC. | $33.34 | 2019-2021 | |
| Allergan, INC. | $29.97 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $28.23 | 2020 | |
| Pulmonx Corporation | $25.29 | 2022 | |
| Shield Therapeutics INC | $23.44 | 2023 | Accrufer |
| Sandoz INC. | $22.14 | 2020 | |
| Verona Pharma, INC. | $22.01 | 2025 | Ohtuvayre |
| Portola Pharmaceuticals, LLC | $20.13 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.84 | 2019 | |
| Horizon Therapeutics Plc | $17.64 | 2020 | |
| Tactile Systems Technology INC | $14.64 | 2025 | Flexitouch Plus, Nimbl |
| Mallinckrodt Enterprises LLC | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Rashkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.